MetLife (MET)
NYSEFinancialsInsurance - LifeSnapshot 2026-09-04
$97.62-1.62%
Close 2026-09-04 · 1-day change
NYSEFinancialsInsurance - LifeSnapshot 2026-09-04
Research Workspace
Put MET beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Financials is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Recent financial performance freshly dropped to the bottom half of its industry.
View ThesisRevenue is growing steadily — about 9% over the past year.
View GrowthMiddle-of-the-pack quality for its industry.
View QualityMiddle-of-the-pack management execution.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskMET's growth relies on maintaining strong earnings and capital returns to shareholders. Recent financial performance has weakened, dropping to the bottom half of its industry. Revenue grew 7% year over year, and the latest quarter beat expectations. It trades at 2.3× price-to-book versus a peer median of 1.3×. This suggests the price reflects less growth than anticipated. If MET cuts guidance on the next call, that could negatively impact expectations. Peer multiples imply a price about 46% above where it trades. This read is provisional.
Trailing returns as of 2026-09-04. MET is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 18 analysts currently covering MET (as of Sep 2026).
Based on 8 Wall Street analysts offering 12-month price targets for MET in the last 4 months.
Continue this research
Compare MET with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| MET Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 12 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Life & Health Insurance — fair value, gap to price, and forward P/E.
Compare the value case
Put MET next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Maintain disciplined capital allocation and return capital to shareholders
Buyback supports capital allocation and shareholder returns.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-04. EPS is implied from price ÷ P/E. Not investment advice.
Current $97.62
The last 12 months of price, then the range of analyst 12-month targets from today’s $97.62.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 25% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Economic concerns may impact premium growth and overall revenues.
Advances: Maintain disciplined capital allocation and return capital to shareholders
Share repurchase supports disciplined capital allocation and shareholder returns.
Advances: Deliver double-digit adjusted earnings per share growth
20% EPS growth supports double-digit growth objective.
Advances: Deliver double-digit adjusted earnings per share growth
Earnings call confirms strong EPS growth and ROE.
Advances: Deliver double-digit adjusted earnings per share growth
Profit rise supports double-digit EPS growth objective.
Advances: Deliver double-digit adjusted earnings per share growth
Profit rise supports double-digit EPS growth objective.
Advances: Grow premiums, fees and other revenues (PFOs) across all segments
New product aligns with revenue growth objectives.
